Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire

04-02

new logo.jpg

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:


Jones Healthcare and Technology Innovation Conference
Location:	Las Vegas, NV
Date:	Wednesday, 9 April 2025
Time:	4:30 pm ET

The Citizens Life Sciences Conference
Location:	New York, NY
Date:	Thursday, 8 May 2025
Time:	1:00 pm ET

Jefferies Global Healthcare Conference
Location:	New York, NY
Date:	Wednesday & Thursday, 4 & 5 June 2025

Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.

About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com

U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524467908"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524467908\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524467908?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524467908","market":"nz","top_or_hot":-1,"title":"Immutep to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/ZYF8BwxDMnxS4hNmrsTIFg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578\" title=\"new logo.jpg\" vspace=\"5\"/>\n<p><strong><strong>SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- </strong></strong> <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a> (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:</p>\n<table>\n<tbody>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jones Healthcare and Technology Innovation Conference</strong></td>\n<td> </td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>Las Vegas, NV</td>\n<td> </td>\n</tr>\n<tr>\n<td>Date:        </td>\n<td>Wednesday, 9 April 2025</td>\n<td> </td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>4:30 pm ET</td>\n<td> </td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>The Citizens Life Sciences </strong><strong>Conference</strong></td>\n</tr>\n<tr>\n<td>Location:</td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Thursday, 8 May 2025</td>\n</tr>\n<tr>\n<td>Time:</td>\n<td>1:00 pm ET</td>\n</tr>\n<tr>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"><strong>Jefferies Global Healthcare Conference</strong></td>\n</tr>\n<tr>\n<td>Location: </td>\n<td>New York, NY</td>\n</tr>\n<tr>\n<td>Date:</td>\n<td>Wednesday &amp; Thursday, 4 &amp; 5 June 2025</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p>Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors &amp; Media section of Immutep’s website.</p>\n<p><strong>About Immutep</strong><br/>Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.<br/></p>\n<p><strong>Australian Investors/Media:</strong><br/>Catherine Strong, Sodali &amp; Co.<br/>+61 (0)406 759 268; catherine.strong@sodali.com<br/><br/></p>\n<p><strong>U.S. Media:</strong><br/>Chris Basta, <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Investor Relations and Corporate Communications<br/>+1 (631) 318 4000; chris.basta@immutep.com<br/><br/></p>\n<br/></body></html>","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-02 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/immutep-participate-upcoming-investor-conferences-120000160.html","article_id":"2524467908","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524467908","pubTimestamp":1743595200,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"SYDNEY, AUSTRALIA , April 02, 2025  -- Immutep Limited  , a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:. Additional information for the Jefferies presentationwill be made available closer to the conference on theEvents pagewithin the Investors & Media section of Immutep’s website.About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.U.S. Media:","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4139":"生物科技","IMM.AU":"IMMUTEP LTD","IMMP":"Immutep Limited","BK7508":"医药生物股"},"translate_title":"Immutep将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9,"IMMP":1},"content_text":"SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:\n\n\n\n \n \n\n\nJones Healthcare and Technology Innovation Conference\n \n\n\nLocation:\nLas Vegas, NV\n \n\n\nDate:        \nWednesday, 9 April 2025\n \n\n\nTime:\n4:30 pm ET\n \n\n\n \n \n \n\n\nThe Citizens Life Sciences Conference\n\n\nLocation:\nNew York, NY\n\n\nDate:\nThursday, 8 May 2025\n\n\nTime:\n1:00 pm ET\n\n\n \n\n\nJefferies Global Healthcare Conference\n\n\nLocation: \nNew York, NY\n\n\nDate:\nWednesday & Thursday, 4 & 5 June 2025\n\n\n \n \n\n\n\nAdditional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.\nAbout ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.\nAustralian Investors/Media:Catherine Strong, Sodali & Co.+61 (0)406 759 268; catherine.strong@sodali.com\nU.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}